IP Library Granted Patent US 11,464,978
Granted Patent B2
US 11,464,978 · App. 16/955,345 · Granted Oct 11, 2022

Treatment of acute medical conditions

Inventors: Daniel John Chew (Middlesex, GB); Matteo Donega (Middlesex, GB); Isha Gupta (Middlesex, GB)
Assignee: Galvani Bioelectronics Limited
A61N1/36071A61N1/0553A61N1/0556A61N1/205A61N1/3616A61N1/36135A61N1/36171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,978
App. No.
16/955,345
Granted
Oct 11, 2022
Kind
B2
Abstract

Electrical stimulation of neural activity in the neural innervation of the spleen that is associated with neurovascular bundles provides a useful way to treat acute medical conditions, such as trauma, hemorrhaging and shock.

Claims (27)

1. A system for stimulating the neural activity of a nerve supplying a spleen for treating an acute medical condition, wherein the nerve is associated with a neurovascular bundle, preferably a splenic arterial nerve, the system comprising:

at least one electrode in signaling contact with the nerve; and

at least one controller electrically coupled to the at least one electrode, the at least one controller configured to control operation of the at least one electrode to apply an electrical signal to the nerve,

wherein the electrical signal has a waveform that comprises one or more pulse trains, wherein a charge density per phase applied to the nerve by the electrical signal is ≥70 μC per cm 2 per phase and ≤1300 μC per cm 2 per phase,

wherein the electrical signal produces an improvement in a physiological parameter indicative of treatment of the acute medical condition,

wherein the improvement in the physiological parameter is any of the group consisting of: restoring a body temperature to between 36° C. and 38° C., restoring a heart rate to 60-100 bpm, restoring a systemic arterial pressure to between 90/60 mmHg and 150/90 mmHg, restoring a systemic venous pressure to about 5 mmHg in a right atrium and about 8 mmHg in a left atrium, restoring a pulmonary pressure to about 15 mmHg, restoring a central venous pressure to in a range of about 3 to 8 mmHg, restoring a breathing rate to 8-14 breaths per minute, an increase in oxygen saturation to ≥94%, an increase in an arterial partial pressure of oxygen to 12-15 kPa, restoring an arterial partial pressure of carbon dioxide to 4.4-6.1 kPa, a reduction of pain sensation, restoring urine output to ≥0.5 ml/kg/hr, increasing a level of consciousness, a reduction in a level of lactate, a change in a level of blood glucose, a change in a level of base deficit in blood and a change in a level of arterial pH, restoring lower levels of pulmonary vascular resistance while increasing systemic vascular resistance and increasing pulmonary capillary wedge pressure, reducing high levels of lipases, and reducing high levels of amylases.

2. The system of claim 1 , wherein the acute medical condition is septic shock.

3. The system of claim 1 , wherein the acute medical condition is severe episodes of lupus.

4. The system of claim 1 , wherein the acute medical condition is hemorrhaging.

5. The system of claim 1 , further comprising a neural interface, the neural interface comprising the at least one electrode.

6. The system of claim 5 , wherein the neural interface is placed around at least one splenic arterial nerve.

7. The system of claim 5 , wherein the neural interface is placed around a splenic artery.

8. The system of claim 5 , wherein the neural interface is placed on at least one splenic arterial nerve.

9. The system of claim 5 , wherein the neural interface is placed on a splenic artery.

10. A method of reversibly stimulating neural activity in a nerve supplying a spleen, wherein the nerve is associated with a neurovascular bundle, the method comprising:

providing the system of claim 1 ;

positioning the at least one electrode in signaling contact with the nerve; and

controlling the operation of the at least one electrode with the at least one controller to apply the electrical signal to at least one splenic arterial nerve to stimulate neural activity.

11. The method of claim 10 , further comprising a neural interface, the neural interface comprising the at least one electrode.

12. The method of claim 11 , wherein the neural interface is placed around the at least one splenic arterial nerve.

13. The method of claim 11 , wherein the neural interface is placed around a splenic artery.

14. The method of claim 11 , wherein the neural interface is placed on the at least one splenic arterial nerve.

15. The method of claim 11 , wherein the neural interface is placed on a splenic artery.

16. A method for treating an acute medical condition, the method comprising applying an electrical signal with a waveform that comprises one or more pulse trains, to stimulate the neural activity of a nerve supplying a spleen, wherein the nerve is associated with a neurovascular bundle, wherein a charge density per phase applied to the nerve by the electrical signal is ≥70 μC per cm 2 per phase and ≤1300 μC per cm 2 per phase, such that the electrical signal produces an improvement in a physiological parameter indicative of treatment of an acute medical condition, wherein the improvement in the physiological parameter is any of the group consisting of: restoring a body temperature to between 36° C. and 38° C., restoring a heart rate to 60-100 bpm, restoring a systemic arterial pressure to between 90/60 mmHg and 150/90 mmHg, restoring a systemic venous pressure to about 5 mmHg in a right atrium and about 8 mmHg in a left atrium, restoring a central venous pressure to in a range of about 3-8 mmHg, restoring a pulmonary pressure to about 15 mmHg, restoring a breathing rate to 8-14 breaths per minute, an increase in oxygen saturation to ≥94%, an increase in an arterial partial pressure of oxygen to 12-15 kPa, restoring an arterial partial pressure of carbon dioxide to 4.4-6.1 kPa, a reduction of pain sensation, restoring urine output to ≥0.5 ml/kg/hr, increasing a level of consciousness, a reduction in a level of lactate, a change in a level of blood glucose, a change in a level of base deficit in blood and a change in a level of arterial pH, restoring lower levels of pulmonary vascular resistance while increasing systemic vascular resistance and increasing pulmonary capillary wedge pressure, reducing high levels of lipases, and reducing high levels of amylases.

17. The method of claim 16 , wherein the acute medical condition is septic shock.

18. The method of claim 16 , wherein the acute medical condition is severe episodes of lupus.

19. The method of claim 16 , wherein the acute medical condition is hemorrhaging.

Assignments (3)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GALVANI BIOELECTRONICS LIMITED
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 070854/0393 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE NAME IS MISTYPED. "ELECTRONICS" SHOULD BE - BIOELECTRONICS- PREVIOUSLY RECORDED AT REEL: 05298 FRAME: 0372. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 22, 2020
From: CHEW, DANIEL JOHN; DONEGA, MATTEO; GUPTA, ISHA
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 052999/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2020
From: CHEW, DANIEL JOHN; DONEGA, MATTEO; GUPTA, ISHA
To: GALVANI ELECTRONICS LIMITED
Reel/Frame 052978/0372 →
Continuity (2)
Provisional Application 62608405 · Dec 20, 2017
Related Publication 20210085977A1 · Mar 25, 2021
Cited By (1)
US 12,377,272